What Corteva’s $35 Million Settlement Changes in the U.S. Pesticide Market

A proposed antitrust settlement between Corteva, the U.S. Federal Trade Commission and 12 states would change how one of the country’s largest crop-protection suppliers can reward distributors for purchases of post-patent pesticides. The order targets the commercial channel between manufacturers and farm retailers rather than pesticide registration or product labels, making its main significance a change in market access for generic competitors.

The parties filed the stipulated order in the U.S. District Court for the Middle District of North Carolina on September 25, 2026, and the FTC announced it on September 28. Corteva would pay the state plaintiffs $35 million and accept restrictions lasting 10 years. The order will have the force of law only after the district judge approves and signs it, so the operational changes should be treated as agreed terms awaiting court entry.

The original 2022 complaint alleged that Corteva and Syngenta used end-of-year loyalty payments to encourage distributors to buy all or nearly all of their requirements for certain active ingredients from the branded supplier. Regulators argued that this made it harder for generic manufacturers to reach farmers after patents and regulatory exclusivity had expired. Both companies disputed the allegations; the settlement resolves the claims against Corteva without resolving the continuing case against Syngenta.

Under the proposed order, Corteva could not condition a payment or other benefit on a distributor buying more than 50% of its requirements for a given pesticide active ingredient from Corteva. It also could not use a program that limits generic purchases to less than a 50% share, recreate those effects through volume targets, or retaliate against customers for dealing with competitors. Importantly, the restrictions apply to all Corteva post-patent active ingredients, not only the three examples named in the litigation.

The 50% threshold reveals what the settlement is designed to change. It does not prohibit rebates, volume discounts or competition for distributor business. It prevents a supplier from using those benefits to make a distributor economically dependent on sourcing most of an off-patent active ingredient from one company. Generic manufacturers should therefore have a clearer path to shelf space and retailer attention, while distributors retain room to negotiate ordinary commercial terms.

Whether farmers see lower invoices will depend on how quickly generic suppliers enter, the number of registered alternatives, distributor stocking decisions and local agronomic demand. Crop-protection products are not interchangeable simply because an active ingredient is off patent: formulation, label scope, state registrations, application support and supply reliability still matter. The settlement removes one alleged barrier to competition, but it does not set prices or compel retailers to carry a particular generic.

The scope is economically meaningful. In its 2022 complaint, the FTC said U.S. farmers purchased more than $10 billion of crop-protection products annually. The agency alleged that Corteva held monopoly or market power in products containing rimsulfuron, used as an herbicide, and oxamyl, used as an insecticide and nematicide. The new order extends beyond those examples, which makes future post-patent portfolio strategy more important than the monetary payment alone.

For Corteva, the settlement creates a compliance constraint around channel programs while leaving the company free to compete through innovation, service, pricing and non-exclusionary incentives. For distributors, it may widen sourcing options but also requires careful redesign of purchasing targets and rebate documentation. For generic manufacturers, the opportunity is access rather than guaranteed sales: they still must win registrations, provide dependable supply and persuade retailers and growers that their products perform.

The broader agribusiness lesson is that patent expiry does not automatically create a competitive farm-input market. Distribution incentives can determine whether lower-cost alternatives become visible and available. The proposed order tests a structural remedy aimed at that bottleneck. Its real effect should be judged over time through generic entry, product availability and transaction prices—not by assuming that a $35 million settlement immediately translates into a specific per-acre saving.